<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04691453</url>
  </required_header>
  <id_info>
    <org_study_id>NFEC-2020-175</org_study_id>
    <nct_id>NCT04691453</nct_id>
  </id_info>
  <brief_title>QM-B and QM-C Hysterectomy for Early Cervical Cancer</brief_title>
  <acronym>QMBCHECC</acronym>
  <official_title>Randomized Clinical Trial Comparing the Oncology Outcome and Safety of QM-B and QM-C Hysterectomy for Early Cervical Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Southern Medical University, China</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Southern Medical University, China</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical research study is to compare the long-term outcomes and safety of&#xD;
      Querleu-Morrow-B(QM-B) and Querleu-Morrow-C(QM-C) hysterectomy for early cervical cancer. In&#xD;
      this study, the surgical approach for QM-B and QM-C hysterectomy will be abdominal.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objective:&#xD;
&#xD;
      To compare 5-year overall survival and 5-year disease-free survival amongst patients who&#xD;
      undergo a QM-B hysterectomy versus those who undergo a QM-C hysterectomy for early stage&#xD;
      cervical cancer.&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
      Compare operation time between arms. Compare blood loss between arms. Compare blood&#xD;
      transfusion between arms. Compare intraoperative complications between arms. Compare&#xD;
      postoperative complications between arms. Compare quality of lifes between arms.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2021</start_date>
  <completion_date type="Anticipated">January 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of overall survival</measure>
    <time_frame>5 years from surgery</time_frame>
    <description>Compare treatment equivalence</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of disease-free survival</measure>
    <time_frame>5 years from surgery</time_frame>
    <description>Compare treatment equivalence</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Operation time</measure>
    <time_frame>Intra-operatively</time_frame>
    <description>Compare operation time between groups by timer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of blood loss</measure>
    <time_frame>Intra-operatively</time_frame>
    <description>Compare blood loss between groups by assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of blood transfusion</measure>
    <time_frame>Intra-operatively</time_frame>
    <description>Compare rate of blood transfusion between groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of intraoperative complications</measure>
    <time_frame>Intra-operatively</time_frame>
    <description>Compare intraoperative complications between groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of postoperative complications</measure>
    <time_frame>6 months from surgery</time_frame>
    <description>Compare postoperative complications between groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life Questionnaires</measure>
    <time_frame>6 months from surgery</time_frame>
    <description>Compare quality of lifes between groups by questionnaire: EORTC CX24. EORTC CX24 for symptom experience, body imageand sexual/vaginal functioning. The scores of EORTC CX24 range from 0 to 100; a higher score represents a higher (&quot;better&quot;) level of functioning, or a higher (&quot;worse&quot;) level of symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pelvic Floor Distress Inventory Questionnaire</measure>
    <time_frame>5 years from surgery</time_frame>
    <description>Compare PFDI between groups by questionnaire PFDI-20. The calculation of the total scores of PFDI-20 range from 0 to 300; the higher the score the greater the perceived impact that pelvic floor dysfuntion has on a patient's life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Costs</measure>
    <time_frame>6 months from surgery</time_frame>
    <description>Compare costs between groups</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">538</enrollment>
  <condition>Uterine Cervical Neoplasms</condition>
  <arm_group>
    <arm_group_label>QM-C Hysterectomy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>QM-C Hysterectomy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>QM-B Hysterectomy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>QM-B Hysterectomy</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>QM-C Hysterectomy</intervention_name>
    <description>This operation corresponds to the classical radical hysterectomy. The lateral border is defined as the medial aspect of the internal iliac artery and vein. Transection of the rectovaginal and rectouterine ligaments is performed at the rectum. Transection of the ventral parametrium ligament is performed at the bladder. Both the vesicouterine and vesicovaginal ligaments are resected. The ureter is completely mobilized and lateralized. The length of the vaginal cuff is adjusted to the vaginal extent of the tumor.</description>
    <arm_group_label>QM-C Hysterectomy</arm_group_label>
    <other_name>Type III radical hysterectomy</other_name>
    <other_name>Radical hysterectomy</other_name>
    <other_name>Type C radical hysterectomy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>QM-B Hysterectomy</intervention_name>
    <description>Type B is the modified radical hysterectomy. The ureter is unroofed and mobilized laterally, permitting transection of the paracervix at the level of the ureteral tunnel. Partial resection of the uterosacral peritoneal fold of the rectouterine ligament (dorsal parametrium) and the vesicouterine (ventral parametrium) ligament also is a standard component of this resection. Approximately 10 mm of the vagina from the caudal edge of the cervix or tumor is resected, without intent to radically resect the paravaginal tissues.</description>
    <arm_group_label>QM-B Hysterectomy</arm_group_label>
    <other_name>Type II radical hysterectomy</other_name>
    <other_name>Modified radical hysterectomy</other_name>
    <other_name>Type B radical hysterectomy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients who have signed an approved Informed Consent&#xD;
&#xD;
          -  18.5â‰¤BMI&lt;28&#xD;
&#xD;
          -  Histologically confirmed primary adenocarcinoma, squamous cell carcinoma or&#xD;
             adenosquamous carcinoma of the uterine cervix;&#xD;
&#xD;
          -  Patients with Histologically confirmed stage IA1 (with lymph vascular invasion), stage&#xD;
             IA2, stage IB1, stage IB2, or stage IIA1 disease(FIGO 2018).&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group(ECOG) Performance Status of 0 or 1.&#xD;
&#xD;
          -  Patients undergoing the Non-Fertility-Sparing surgery.&#xD;
&#xD;
          -  Patients undergoing abdominal surgery.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The life expectancy of the patient is less than 6 months.&#xD;
&#xD;
          -  Patients with serious medical diseases.&#xD;
&#xD;
          -  Patients with contraindications to surgery or anesthesia.&#xD;
&#xD;
          -  Preoperative imaging studies suggest metastasis to pelvic lymph nodes or para-aortic&#xD;
             lymph nodes.&#xD;
&#xD;
          -  Patient asks to preserve fertility.&#xD;
&#xD;
          -  The patient requested direct radiation therapy.&#xD;
&#xD;
          -  Patients with adjuvant radiotherapy or chemotherapy before surgery.&#xD;
&#xD;
          -  Patients judged by the investigator to be unsuitable to participate in this trial.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chunlin Chen, Doctor</last_name>
    <role>Study Chair</role>
    <affiliation>Nanfang Hospital of Southern Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chunlin Chen, Doctor</last_name>
    <phone>008613725263051</phone>
    <email>jieru@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Obstetrics and Gynecology, Nanfang Hospital, Southern Medical University, No. 1838, Guangzhou Avenue, Guangzhou 510515</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510515</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chunlin Chen, Doctor</last_name>
      <phone>8602062787562</phone>
      <email>jieru@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>October 20, 2020</study_first_submitted>
  <study_first_submitted_qc>December 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 31, 2020</study_first_posted>
  <last_update_submitted>December 28, 2020</last_update_submitted>
  <last_update_submitted_qc>December 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Southern Medical University, China</investigator_affiliation>
    <investigator_full_name>Chen Chunlin</investigator_full_name>
    <investigator_title>Director, Head of Obstetrics and Gynecology, Principal Investigator, Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>Cervical cancer</keyword>
  <keyword>QM-B</keyword>
  <keyword>QM-C</keyword>
  <keyword>Oncology outcome</keyword>
  <keyword>Safety</keyword>
  <keyword>Hysterectomy</keyword>
  <keyword>Radical Hysterectomy</keyword>
  <keyword>Abdominal</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

